Product Highlight

DFE’s nitrosamine mitigation strategies

Product Highlight

Pharmaceuticals

United for safety – why Nitrosamine control matters

1
DFE’s nitrosamine mitigation strategies
2
Nitrosamine mitigation solutions from Roquette Health & Pharma
3
United for safety - Navigating innovation with nitrosamine risks
4
Webinar: United for safety - smarter excipients for nitrosamine risk mitigation
5
Webinar: From lab to label - Analytical method advances in measuring nitrite in pharmaceutical excipients

Nitrosamine contamination has become one of the most significant formulation challenges in recent years, driven by global regulatory scrutiny and the need for robust quality by design (QbD) approaches.

DFE Pharma has taken a proactive role in supporting formulators by providing excipient‑based mitigation strategies and digital tools that help quantify and reduce nitrosamine‑formation risks throughout the drug product lifecycle.

DFE excipient‑based mitigation approach

DFE Pharma identifies excipients as a key, yet often underestimated risk factor in the formation of nitrosamines. Although the likelihood of nitrosamines being present in excipients is generally low, trace levels of nitrites can initiate nitrosamine formation under specific conditions, particularly in formulations containing vulnerable amines.

Low‑nitrite excipients

Studies show substantial variability in nitrite levels across excipients and suppliers, with differences even within the same excipient class. DFE Pharma has therefore proactively tested its entire excipient portfolio under current EMA and FDA guidance, confirming that nitrite levels in its excipients belong to the lowest in the industry. This allows formulators to significantly reduce precursor availability and therefore reduce overall nitrosamine‑formation potential via careful excipient selection.

Supplier qualification & risk assessment

DFE Pharma highlights that choosing excipients from suppliers with controlled, well‑documented production and analytical processes is critical to minimising variability. Their approach encourages formulators to compare excipient types and suppliers during risk assessments, ensuring that nitrosamine precursors are kept at minimal levels prior to manufacturing.

Support through expert guidance

DFE Pharma provides direct technical support and detailed risk‑assessment insights, enabling formulation scientists to understand excipient contribution, select optimal ingredients, and implement strategies that lower nitrosamine‑related risks early in development. DFE Pharma can supply support documentation and safety assessments for all its excipients with the following information:

Use of sodium nitrate or any other nitrosation agent in the manufacturing of DFE excipients.
Analysis of nitrite, nitrate, and nitrosamine levels of all DFE Pharma products.
Use and origin of water in the manufacturing process.
Potential presence of secondary or tertiary amines in the excipients.
Use or potential presence of any amide, primary amines, or ammonium salt.
Use or recovery of nitrogen-containing solvents.
Manufacturing equipment and cross-contamination

Featured products for nitrosamine mitigation

DFE Pharma’s portfolio includes several excipients with especially low nitrite levels, making them strong mitigation assets for sensitive drug products. Although the site does not list specific branded excipients in the overview page, it emphasises that the full DFE excipient range has been benchmarked, and many of their high‑purity grades (e.g., lactose, superdisintegrants) have demonstrably low nitrite content based on internal screening.

Product class	Product name	Nitrate level
Milled/sieved lactose	Pharmatose®	<0.030ppm
DC lactose	Supertab®	<0.030ppm
Superdisintegrant	Primojel®	<0.1ppm
Superdisintegrant	Primolose®	<0.1ppm
Starch	Prejel®	<0.1ppm

Nitrosamine Risk Mitigation Calculator

A highlight among DFE’s mitigation tools is the Nitrosamine Risk Mitigation Calculator, a free, browser‑based tool designed to estimate the potential formation of nitrosamines based on formulation composition. The tool allows users to input:

Excipient amounts
Conversion percentages
Nitrosamine molecular weights
Tablet weight and product strength

It then calculates theoretical nitrosamine formation levels, helping formulators compare scenarios, optimise excipient combinations, and reduce reliance on trial‑and‑error experimentation.

This calculator is especially useful for:

Comparing excipient suppliers
Quantifying the impact of switching to low‑nitrite excipients
Supporting QbD strategies during development
Documenting risk assessments for regulatory submissions

Conclusion

DFE Pharma offers a holistic, excipient‑driven strategy to minimise nitrosamine formation:

Lowest-in-class nitrite excipients
Full documentation package
Free online risk calculator
Expert technical support

Together, these solutions help pharmaceutical companies meet stringent regulatory expectations while safeguarding patient safety.

Partner with IMCD for safer formulations

Nitrosamine mitigation isn’t just a compliance hurdle, it’s a commitment to patient well-being. DFE’s robust portfolio of low-nitrite excipients, backed by rigorous analytical screening and regulatory insight, positions us as a trusted partner for pharmaceutical manufacturers striving to deliver high-quality, safe medicines worldwide.

Discover how our solutions can elevate your formulation strategy. Request some of our nitrosamine mitigation products today.